TR200906322A2 - Granules with improved solubility and stability properties. - Google Patents

Granules with improved solubility and stability properties.

Info

Publication number
TR200906322A2
TR200906322A2 TR2009/06322A TR200906322A TR200906322A2 TR 200906322 A2 TR200906322 A2 TR 200906322A2 TR 2009/06322 A TR2009/06322 A TR 2009/06322A TR 200906322 A TR200906322 A TR 200906322A TR 200906322 A2 TR200906322 A2 TR 200906322A2
Authority
TR
Turkey
Prior art keywords
improved solubility
granules
stability properties
stability
properties
Prior art date
Application number
TR2009/06322A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2009/06322A priority Critical patent/TR200906322A2/en
Priority to PCT/TR2010/000167 priority patent/WO2011034513A1/en
Priority to EP10801007A priority patent/EP2467129A1/en
Publication of TR200906322A2 publication Critical patent/TR200906322A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

Mevcut buluş, tek başına veya HCTZ gibi bir terapotik ajanla kombinasyon halindeki ramiprili içeren çözünürlük ve stabilite özellikleri geliştirilmiş farmasötik bileşimlere, bu bileşimlerin hazırlanma yöntemine ve tıbbi kullanımına ilişkindirThe present invention relates to pharmaceutical compositions with improved solubility and stability properties, method of preparation and medical use of ramipril alone or in combination with a therapeutic agent such as HCTZ.

TR2009/06322A 2009-08-17 2009-08-17 Granules with improved solubility and stability properties. TR200906322A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2009/06322A TR200906322A2 (en) 2009-08-17 2009-08-17 Granules with improved solubility and stability properties.
PCT/TR2010/000167 WO2011034513A1 (en) 2009-08-17 2010-08-13 The granules with improved solubility and stability
EP10801007A EP2467129A1 (en) 2009-08-17 2010-08-13 The granules with improved solubility and stability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2009/06322A TR200906322A2 (en) 2009-08-17 2009-08-17 Granules with improved solubility and stability properties.

Publications (1)

Publication Number Publication Date
TR200906322A2 true TR200906322A2 (en) 2011-07-21

Family

ID=43568838

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/06322A TR200906322A2 (en) 2009-08-17 2009-08-17 Granules with improved solubility and stability properties.

Country Status (3)

Country Link
EP (1) EP2467129A1 (en)
TR (1) TR200906322A2 (en)
WO (1) WO2011034513A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163579B2 (en) * 2004-04-14 2007-01-16 H.B. Fuller Licensing & Financing Inc. Method of making water resistant corrugated boards

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
DE3226768A1 (en) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (en) 1987-11-24 1989-06-08 Hoechst Ag STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS
PL344586A1 (en) 1998-06-05 2001-11-05 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
US20030225124A1 (en) 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
MXPA04006892A (en) 2002-01-15 2004-10-15 Ranbaxy Lab Ltd Stable pharmaceutical compositions comprising ace inhibitor(s).
US20050118259A1 (en) 2002-01-15 2005-06-02 Renir Eyjolfsson Formulations of quinapril and related ace nhibitors
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
WO2004064809A1 (en) 2003-01-22 2004-08-05 Sandoz Ag Solid pharmaceutical composition comprising ramipril
US20050069586A1 (en) * 2003-06-26 2005-03-31 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives
GB2404336A (en) 2003-07-30 2005-02-02 Cipla Ltd Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20080234353A1 (en) 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
US20060045911A1 (en) 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
ZA200704768B (en) 2004-11-05 2008-08-27 King Pharmaceuticals Res & Dev Stabilized ramipril compositions and methods of making
CA2628955A1 (en) 2005-11-07 2007-05-18 Edward S. Wilson Compositions of stabilized ramipril in combination with another active agent
WO2008001184A2 (en) 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Solid composition
WO2008000040A1 (en) 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
GB0624084D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
PL382311A1 (en) 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Pharmaceutical composition with improved stability containing inhibitor of acethylolinoesterasis or its pharmaceutically admitted salt and its production method
WO2008132756A1 (en) 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril

Also Published As

Publication number Publication date
EP2467129A1 (en) 2012-06-27
WO2011034513A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
CY1119616T1 (en) HUMAN ANTI-DUMP DRUG CONSUMPTION AGAINST TISSUE
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
CY1118813T1 (en) PHARMACEUTICAL COMPOSITIONS OF TRAMADOL AND COXYL-CYLINDERS
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2009014235A (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UA109010C2 (en) Morpholino pyrividines and their use in therapy
IN2012DN01233A (en)
MA33803B1 (en) BENZODIAZEPINE BROMODOMAINE INHIBITOR
EA201100971A1 (en) DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION
UA108105C2 (en) Nitrogen-containing heteroaryl compounds
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
MX2011009847A (en) Anthelmintic agents and their use.
MX348823B (en) Stable formulations of linaclotide.
EA201070327A1 (en) CATECHOLAMINE DERIVATIVES AND THEIR DEVICES
UA109037C2 (en) Triazolepyridins
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
TR200806298A2 (en) Pharmaceutical formulation
MX2015011614A (en) Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX342947B (en) Treatment of type 2 diabetes.
GEP20135859B (en) Stable combined pharmaceutical composition
TR201009167A2 (en) Pharmaceutical granules containing cephalosporin.
TR200806300A2 (en) Solubility enhancing pharmaceutical formulation
TR200906322A2 (en) Granules with improved solubility and stability properties.